We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preoperative Hepatic Arterial Infusion Chemotherapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by IRCCS San Raffaele.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00522509
First Posted: August 29, 2007
Last Update Posted: August 29, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
IRCCS San Raffaele
August 28, 2007
August 29, 2007
August 29, 2007
December 1995
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Preoperative Hepatic Arterial Infusion Chemotherapy
Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases
To assess the feasibility and results of liver resection after preoperative hepatic artery infusion (HAI) chemotherapy with FUDR.

Between 1995 and 2004, 239 patients with isolated colorectal liver metastases received HAI chemotherapy with neoadjuvant intent. Fifty of these patients underwent subsequent curative liver resection (HAI group).

Postoperative morbidity, liver function tests, and long term outcomes were evaluated. Adverse events related to HAI chemotherapy were also evaluated.

Observational
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Not Provided
Not Provided
Not Provided
Not Provided
Colorectal Liver Metastases
Drug: Floxuridine FUDR
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Unresectable liver metastases
  • Potentially resectable liver metastases

Exclusion Criteria:

  • Extrahepatic disease
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT00522509
Neoadjuvant HAIC
Not Provided
Not Provided
Not Provided
Not Provided
IRCCS San Raffaele
Not Provided
Principal Investigator: Luca Aldrighetti, M.D, PhD Department of Surgery - Liver Unit, Scientific Institute San Raffaele,
IRCCS San Raffaele
May 2007